SapVax is advancing discoveries made by researchers from the University of Auckland in New Zealand. Their academic founders have developed a novel chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate fully-synthetic, self-adjuvanting cancer vaccines. The Sapvax... Read more